Abstract
The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation- associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.
Keywords: Innate immune cells, immunoregulatory receptors, triggering receptor expressed on myeloid cells, inflammation, inflammatory diseases, cancer, disease models, therapy.
Current Pharmaceutical Design
Title:Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Volume: 22 Issue: 41
Author(s): Maria Carla Bosco, Federica Raggi and Luigi Varesio
Affiliation:
Keywords: Innate immune cells, immunoregulatory receptors, triggering receptor expressed on myeloid cells, inflammation, inflammatory diseases, cancer, disease models, therapy.
Abstract: The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation- associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.
Export Options
About this article
Cite this article as:
Bosco Carla Maria, Raggi Federica and Varesio Luigi, Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer, Current Pharmaceutical Design 2016; 22 (41) . https://dx.doi.org/10.2174/1381612822666160826110539
DOI https://dx.doi.org/10.2174/1381612822666160826110539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews The Use of Phages for the Removal of Infectious Biofilms
Current Pharmaceutical Biotechnology Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology Scintigraphic Imaging of Inflammatory Processes
Medicinal Chemistry Reviews - Online (Discontinued) Pulmonary Arterial Hypertension (PAH) Group 1 (Part A): Overview, Classification, Clinical Subsets, and Workup
Current Respiratory Medicine Reviews Editorial (Thematic Issue: From Nuisance to State-of-the-Art: FDG-PET/CT Imaging of Infection and Inflammation)
Current Molecular Imaging (Discontinued) Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Polymer Anchored Gold Nanoparticles: Synthesis, Characterization and Antimicrobial Activities
Nanoscience & Nanotechnology-Asia Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Non-Steroidal Targets in the Diagnosis and Treatment of Endometriosis
Current Medicinal Chemistry